In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 60 of 96

Sort by

Keyword or reference number: in`Remove $Keyword or reference number: in filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]	Technology appraisal guidance	3 September 2026
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Technology appraisal guidance	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance	15 October 2026
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	3 September 2026
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]	Technology appraisal guidance	TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]	Technology appraisal guidance	TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]	Technology appraisal guidance	TBC

Results per page

10
25
50
All